English

Interim Report January - June 2010

Report this content

​Net sales increased by 1.9 million SEK and EBIT increased by 1.4 million SEK, excluding extraordinary income from Kraft in second quarter 2009

  • Net sales for the reporting period amounted to 31.9 million SEK (35.4) and for the second quarter to 16.0 million SEK (19.5). (Net sales 2009 excluding extraordinary income from Kraft Q1-Q2: 30.0 and Q2: 14.1.)

 

  • EBIT for the reporting period amounted to 5.8 million SEK (8.9) and for the second quarter to 2.7 million SEK (6.8). (EBIT 2009 excluding extraordinary income from Kraft Q1-Q2: 3.5 and Q2: 1.4.)  

 

  • Profit after tax for the reporting period amounted to 4.5 million SEK (7.2) and for the second quarter to 2.1 million SEK (5.1). (Profit after tax 2009 excluding extraordinary income from Kraft Q1-Q2: 3.2 and Q2: 1.1)

 

  • After tax earnings per share for the reporting period amounted to 0.48 SEK (0.77) and for the second quarter to 0.23 SEK (0.54). (After tax earnings per share 2009 excluding extraordinary income from Kraft Q1-Q2: 0.34 and Q2: 0.11.)

 

  • Cash flow for the reporting period amounted to 4.8 million SEK (9.2) and for the second quarter to 3.1 million SEK (5.8). (Cash flow 2009 excluding extraordinary income from Kraft Q1-Q2: 3.8 and Q2: 0.4)

 

  • Agreement with Generica Ltd. regarding launch of Probi’s dietary supplement for gut health in the Czech Republic and Slovakia.

 

  • Dietary Supplements net sales were 4.9 million SEK (3.5), an increase with 39 per cent compared to the second quarter of 2009.

 

  • Royalty proceeds from ProViva were 10.7 million SEK (9.4), an increase with 14 per cent compared to the second quarter of 2009.

 

CEO’s COMMENTS:

 

“Our entire business continues to develop positively in the second quarter of 2010. Sales following the launch of  ProbiMage and ProbiFrisk in Sweden are higher than expected, we expand sales of dietary supplements to new markets and sales of ProViva increase steadily,” says Michael Oredsson, CEO of Probi.  

FOR FURTHER INFORMATION, CONTACT:

 

Michael Oredsson, CEO Probi, phone: +46 46 286 89 23 or +46 707 18 89 30; e-mail: michael.oredsson@probi.se

ABOUT PROBI

 

Probi is a leading player in probiotics research and the development of efficient and well-documented probiotics. The research areas include: gastrointestinal tracts, immune system, metabolic syndrome and stress and recovery. Probi’s customers are leading companies in the functional foods and dietary supplement business areas. Total income for 2009 was MSEK 66.2, of which the majority represented royalties. Probi’s share is listed on the Nasdaq OMX Stockholm, Small Cap. Probi has approximately 4,500 shareholders. For more information, please visit www.probi.se.

Subscribe

Documents & Links